Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Ultragenyx Pharmaceutical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ultragenyx expects to reach and sustain profitability in 2027, with revenue approaching $1 billion next year. It has cut staff by about 20% and R&D spending by 50%, and says its cash balance exceeds $700 million after selling two priority review vouchers.
  • The company says launches of gene therapies FAYUVI and GENGLYCOS are progressing, though it plans to wait for more launch experience before issuing product-specific forecasts. Executives said only a relatively small contribution from the therapies may be needed to support the profitability goal.
  • Ultragenyx is discussing next steps with the FDA for setrusumab after its OI study missed its fracture-rate endpoint; a further trial remains possible. The company has set aside its Angelman syndrome program.
  • Interested in Ultragenyx Pharmaceutical? Here are five stocks we like better.

Ultragenyx Pharmaceutical NASDAQ: RARE expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference.

CEO Emil Kakkis said the company is heading toward $1 billion in revenue next year and expects “meaningful profitability.” The outlook follows setbacks in its setrusumab program for osteogenesis imperfecta, or OI, and its Angelman syndrome program. Ultragenyx plans to continue pursuing setrusumab but has set aside the Angelman program, he said.

The company has reduced its staff by approximately 20% and cut research and development spending by 50%, Kakkis said. It also sold two priority review vouchers for approximately $350 million, bringing its cash balance to more than $700 million, he said.

Profitability and Commercial Growth

CFO Howard Horn said Ultragenyx projects profitability in 2027 and intends to sustain it. The company plans to keep R&D spending below $350 million and selling, general and administrative expenses below $375 million next year.

The forecast includes the possibility of another setrusumab trial, Horn said. He added that the company has sufficient balance-sheet strength to reach profitability without raising additional capital.

Horn said the company’s existing four-product business has historically grown by more than 20% annually, although he did not provide a growth forecast. Kakkis pointed to expansion into additional territories, including Japan and the Middle East, as a contributor to that growth.

Asked about potential competition for Crysvita after patent expiration, Kakkis said Ultragenyx and partner Kyowa Kirin are working on potential next-generation versions. The companies hope to improve properties such as potency or dosing intervals, he said.

Gene Therapy Launches

Kakkis said the launches of FAYUVI and GENGLYCOS are going well, with more immediate interest in FAYUVI from families affected by Sanfilippo syndrome. He said the company plans to provide launch information in January, including treatment-center, patient-start and revenue figures.

Ultragenyx does not plan to issue product-specific forecasts for the two therapies until it has approximately six quarters of launch experience, Kakkis said. Horn said the company has not provided guidance for the launches, but that extrapolating normal growth from the existing business would leave a relatively small revenue contribution needed from the two gene therapies to support profitability.

Setrusumab Discussions Continue

Kakkis said Ultragenyx is discussing next steps for setrusumab with the Food and Drug Administration after the ORBIT study missed its fracture-rate endpoint. He attributed the result in part to a lower-than-expected fracture rate among enrolled patients.

The CEO pointed to improvements in bone mineral density and other measures, as well as a post hoc analysis showing fracture reductions among patients with higher baseline fracture rates. He said patients had been assigned to groups based on fracture history, but the subset analysis itself was not prespecified for statistical analysis.

Kakkis cautioned that bone mineral density is not currently accepted by the FDA as a surrogate endpoint for OI. While the company is exploring alternatives, he said investors should not assume a further trial would occur only after approval. If another study is needed, it would probably resemble the COSMIC study’s active-comparator design, he said. He did not provide a timeline for an FDA update.

OTC Gene Therapy

Ultragenyx is also studying DTX301, a gene therapy for ornithine transcarbamylase deficiency, in the open-label portion of its Phase 3 study. Kakkis said the company is assessing whether some patients can discontinue existing drugs and dietary restrictions while maintaining disease control.

He said the blinded portion showed improved ammonia control and patient-reported outcomes, and argued that those data should support approval. The open-label portion is intended to provide further information on whether patients can safely move away from current care, he said.

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines